Composition and method for controlling intestinal pathogenic organisms

Abstract

An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen, composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.

1 . A multivalent antigen composition, comprising:
 seven field strains of  E. coli;        Pseudomona aeruginosa;        Aerobacter aerogenes:        Salmonella enteritidis;        Salmonella typhimurium;        Salmonella agona;  and     Salmonella Kentucky,      the multivalent antigen composition stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism.   
     
     
         2 . The multivalent antigen composition of  claim 1 , wherein the intestinal pathogenic organism, comprises  Clostridium perfringens.    
     
     
         3 . The multivalent antigen composition of  claim 1 , wherein the intestinal pathogenic organism comprises  Salmonella  species. 
     
     
         4 . The multivalent antigen composition of  claim 1 , wherein the intestinal pathogenic organism, comprises  Escherichia coli.    
     
     
         5 . The multivalent antigen composition of  claim 1 , comprising an antigen vaccine. 
     
     
         6 . The multivalent antigen composition of  claim 5 , wherein the vaccine comprises an in ovo antigen vaccine. 
     
     
         7 . The multivalent antigen composition of  claim 5 , wherein the antigen vaccine further comprises a Marek's disease vaccine. 
     
     
         8 . The multivalent antigen composition of  claim 7 , wherein the antigen vaccine and the Marek's disease vaccine are present in a ratio of 1:1. 
     
     
         9 . The multivalent antigen composition of  claim 1 , wherein the seven field strains comprise ATCC strain 25922, a University of Delaware field isolate, and live Delaware field isolates. 
     
     
         10 . A bacterin vaccine, comprising:
 about 67% of seven field strains of  E. coli  , the strains selected from the group consisting of ATCC strain 25922, a University of Delaware field isolate, and five Delamarva field isolates;   about 10%  Pseudomona aeruginosa;      about 10%  Aerobacter aerogenes;      about 4%  Salmonella enteritidis;      about 3%  Salmonella typhimurium,      about 3%  Salmonella agana;  and   about 3%  Salmonella Kentucky.      
     
     
         11 . The bacteria vaccine of  claim 10 , wherein each of the seven field strains of  E. coli  are present in substantially equal proportions. 
     
     
         12 . The bacterin vaccine of  claim 10 , wherein the  Pseudomona aeruginosa  comprises ATCC strain 27853. 
     
     
         13 . The bacterin vaccine of Claim  10 , wherein then  Salmonella enteritidis  comprises ATCC strain 13076. 
     
     
         14 . The bacterin vaccine of Claim  10 , wherein the  Salmonella typhimurium  comprises ATCC strain 14028. 
     
     
         15 . A method for reducing transmission of pathogenic gastrointestinal organisms, comprising:
 inoculating an avian species in ovo at about 18 days embryonic age with the vaccine according to  claim 10 .   
     
     
         16 . An in ovo vaccine, comprising:
 a bacterin vaccine including:
 seven field strains of  E. coli  , with, at least one field strain, consisting of ATCC strain 25922 of  E. coli.  and wherein each field strain is present in substantially equal amounts, 
 ATCC strain 27853 of  Pseudomona aeruginosa.    
   Aerobacter aerogenes,    
 ATCC strain 13076 of  Salmonella enteritidis,    
 ATCC Strain 14028 of  Salmonella typhimurium.    
   Salmonella agona,  and 
   Salmonella Kentucky;  and 
   a Marek's disease vaccine.   the in ovo vaccine reducing a concentration of at least one pathogenic organism in a gastrointestinal tract of an inoculated avian species.   
     
     
         17 . The in ovo vaccine of  claim 16 , wherein the Marek's disease vaccine is selected from the group consisting of HVT vaccines, SB-1 vaccines, and combinations thereof. 
     
     
         18 . The in ovo vaccine of  claim 16 , wherein the pathogenic organism is selected from the group consisting of  E. coli  spp.,  Salmonella  spp., or a combination thereof. 
     
     
         19 . The in ovo vaccine of  claim 16 , wherein the avian species is a domestic fowl selected from the group consisting chickens, ducks, geese and turkeys. 
     
     
         20 . A method for reducing transmission of pathogenic gastrointestinal organisms, comprising:
 inoculating an avian species in ovo at about 18 days embryonic age with the vaccine according to  claim 16 .